OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

by Paul | 8th September 2026 | News

London and New York, NY, September 8, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced...
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

by Paul | 7th July 2026 | News

London and New York, NY, July 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced...
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

by Paul | 18th March 2026 | News

London and New York, NY, March 18, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new...
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

by Paul | 10th February 2026 | News

Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli will lead the clinical and regulatory strategy to advance the...
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

by Paul | 30th January 2026 | News

London and New York, NY, January 30, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that...
« Older Entries

Recent Posts

  • OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
  • OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
  • OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
  • OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
  • OKYO Pharma Announces Purchase of Shares by Director

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023